Georgia McCann, MD
Gynecologic Oncology · San Antonio, TXNPI 1548325582
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $260 of the $410 with a category attached, or 63.5%. 5 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 50.7% of the total. Reporting peaked in 2022 at $149 and has fallen 64.9% since, to $52 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in TX, where the typical reported total is $3,034.
Across 6 payments — averaging $68.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$208
- Seagen Inc.$99
- Intuitive Surgical$50
- Genentech USA, Inc.$27
- Johnson & Johnson$26
Across 21 payments — averaging $3610.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$47K
- Tesaro, Inc.$29K
What the payments were for
- Food & beverage$26064%
- Education$14936%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 2 | $208 |
| Seagen Inc. | 1 | $99 |
| Intuitive Surgical | 1 | $50 |
| Genentech USA, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PreciseTumor$113
How this compares
$410 in reported general payments places this provider in the 10th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 12 | $124,721 |
| Megestrol Acetate | 16 | $895 |
| Clobetasol Propionate | 12 | $337 |
| Ibuprofen | 12 | $330 |
| Gabapentin | 23 | $166 |
| Sertraline Hcl | 13 | $10 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in San Antonio
- Joseph de la GarzaSan Antonio$234K
- Antonio Santillan-GomezSan Antonio$162K
- James SzenderSan Antonio$36K
- James MarkSan Antonio$6K
- Jaron MarkSan Antonio$6K
- Edward KostSan Antonio$6K
- Kassondra GrzankowskiSan Antonio$5K
- Stuart WinklerSan Antonio$5K
- Corinne JordanSan Antonio$4K
- Robert ColemanHouston$864K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.